Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Canva, Generate Biomedicines, and 370+ companies. 5-min read every Tuesday.
Canva is the world's leading design platform with 250M+ users — valued at $48B with $770M raised. Track IPO timeline, funding rounds, and readiness score.
| Industry | Design & Creative |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $42B |
| Total Funding | $770M |
| Headquarters | Sydney, Australia |
Generate Biomedicines uses AI diffusion models and large-scale protein language models to generate novel therapeutic proteins and entire molecules from scratch — designing drugs that have never existed before in weeks instead of years. Valued at $1.2B with $400M raised from Andreessen Horowitz, Generate Biomedicines has multiple preclinical programs in oncology and immunology. Major AI biotech IPO candidate as AI-driven protein generation transforms pharmaceutical R&D from a trial-and-error process into a computational engineering discipline.
| Industry | Biotechnology |
| Stage | Series D |
| IPO Status | Private |
| Valuation | $4.2B |
| Total Funding | $150M |
| Headquarters | Cambridge, MA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Canva is valued at $42B. Generate Biomedicines is valued at $4.2B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Canva reported 4000000000 revenue in 2025. Generate Biomedicines's revenue is not publicly disclosed. Revenue figures are sourced from TechStackIPO's company database and updated as new data becomes available.
Canva filed an S-1 in November 2025 and is actively in the IPO pipeline. Generate Biomedicines is currently private. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Canva has raised $770M. Generate Biomedicines has raised $150M.
Canva operates in Design & Creative, while Generate Biomedicines operates in Biotechnology.
Canva is a Design & Creative company valued at $42B with $770M raised. Generate Biomedicines is a Biotechnology company valued at $4.2B with $150M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Canva and Generate Biomedicines through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.